Andres Montefeltro
Granada, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Corrigendum to "Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys" [EBioMedicine 2020; 59:102944].
Journal: EBioMedicine
Published: December 01, 2021
Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy.
Journal: Translational psychiatry
Published: July 26, 2021
Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Journal: International journal of molecular sciences
Published: February 09, 2021
Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys.
Journal: EBioMedicine
Published: February 17, 2020
Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 06, 2017
Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration.
Journal: Molecular psychiatry
Published: October 10, 2014
RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis.
Journal: Translational psychiatry
Published: January 17, 2013
New antidepressant strategy based on acute siRNA silencing of 5-HT1A autoreceptors.
Journal: Molecular psychiatry
Published: May 24, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026